SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-23-082441
Filing Date
2023-03-29
Accepted
2023-03-28 19:12:05
Documents
2

Document Format Files

Seq Description Document Type Size
1 424B5 d434040d424b5.htm 424B5 7319
2 GRAPHIC g434040g19e51.jpg GRAPHIC 39465
  Complete submission text file 0001193125-23-082441.txt   58684
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-260069 | Film No.: 23771314
SIC: 2836 Biological Products, (No Diagnostic Substances)